Key result
Early inadvertent DTRP6 GnRH exposure shows no teratogenic or deleterious effects through 18 months.
Why the study?
Early follicular use of long-acting GnRH analogues in IVF programs raised concerns about potential teratogenic effects during pregnancy.
Does inadvertent administration of DTRP6 GnRH microcapsules during early pregnancy cause teratogenesis?
Case Report (n=1)
Does inadvertent administration of DTRP6 GnRH microcapsules during early pregnancy cause teratogenesis?
Inadvertent administration of DTRP6 GnRH microcapsules in early pregnancy did not result in teratogenesis in this single case report.
No adverse outcome in this single early-pregnancy exposure; leaves open teratogenic risk assessment pending additional cases.
Early follicular use of long-acting analogues of gonadotrophin releasing hormone (GnRH) in IVF programmes has caused some concern with respect to its teratogenic potential. In the case reported here, an injection of DTRP6 GnRH microcapsules was given in the 5th week of a spontaneous unsuspected pregnancy. No deleterious effect or teratogenesis of the embryo could be demonstrated at birth or 18 months later.
No takes yet. Share an insight, caveat, or question.
Golan et al. (1990) conducted a case report in Spontaneous unsuspected pregnancy (n=1). DTRP6 GnRH microcapsules was evaluated on Deleterious effect or teratogenesis of the embryo. Inadvertent administration of DTRP6 GnRH microcapsules in the 5th week of pregnancy resulted in no demonstrable deleterious effect or teratogenesis at birth or 18 months later.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: